Author of the publication

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

, , , , , , , , , , , , , , , and . Lancet, 359 (9323): 2065–2071 (2002)

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

 

Other publications of authors with the same name

Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts, , , , , , and . Blood, 86 (10): 3970–3978 (1995)Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF, , , , , , , , , and 3 other author(s). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 12 (4): 471–477 (2001)Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group, , , , , , , , , and . Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 (3): 580–586 (1994)Humoral immune responses against the immature laminin receptor protein show prognostic significance in patients with chronic lymphocytic leukemia, , , , , , , , , and 4 other author(s). Journal of immunology (Baltimore, Md. : 1950), 180 (9): 6374–6384 (2008)Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL, , , , , , , , , and 3 other author(s). Blood, 104 (3): 634–641 (2004)Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL), , , , , , , , , and 5 other author(s). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 19 (3): 545–552 (2008)CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group, , , , , , , , , and . Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 23 (5): 1267–1273 (2012)Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60), , , , , , , , , and 16 other author(s). The Lancet Oncology, 9 (2): 105–116 (2008)Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era, , , , , , and . Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 (14): 2373–2380 (2010)Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group, , , , , , , , , and . Blood, 116 (18): 3418–3425 (2010)